Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 361 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tumor markers Clear all

Conditions: Mixed Tumor, Mullerian
Interventions: Carboplatin, Paclitaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 4
States / cities: Loma Linda, California • Orlando, Florida • Houston, Texas

Conditions: Non-melanoma Skin Cancer
Interventions: topical diclofenac daily, placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Prostate Cancer
Interventions: microarray analysis, diagnostic laboratory biomarker analysis; Genetic · Other
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 10
States / cities: Atlanta, Georgia • Springfield, Illinois • City of Saint Peters, Missouri + 4 more

Conditions: Cancer
Interventions: Triciribine Phosphate Monohydrate; Drug
Lead sponsor: Prescient Therapeutics, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Provista Diagnostics, Inc; Industry
Eligibility: 25 Years to 49 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 8
States / cities: Phoenix, Arizona • Sacramento, California • San Diego, California + 5 more

Conditions: Breast Cancer
Interventions: pharmacodynamic analysis; Drug
Lead sponsor: National Institute of General Medical Sciences (NIGMS); NIH
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 3
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan

Conditions: Gastric Cancer, Lung Cancer
Interventions: respiration correlated CT scan; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Gastrointestinal Cancer, Head and Neck Cancer, Breast Cancer, Chemotherapy Effect, 5-Fluorouracil Toxicity
Interventions: Arterial blood pressure, Skin microcirculatory blood flow, Brachial artery blood flow, Venous blood draw; Other
Lead sponsor: Kansas State University; Other
Eligibility: 21 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Manhattan, Kansas

Conditions: Intracranial Venous Blood, Brain Cancers, Liquid Biopsy, Evaluate the Safety
Interventions: blood sampling; Diagnostic Test
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer
Interventions: Endoscopic Ultrasound (EUS) for fiducial placement; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions: compliance monitoring, systemic chemotherapy, medical chart review, study of socioeconomic and demographic variables, survey administration, cognitive assessment, psychosocial assessment and care; Behavioral · Drug · Other + 1 more
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: Cleveland, Ohio • Mentor, Ohio • Orange, Ohio + 2 more

Conditions: Refractory Solid Tumors, Lymphoma
Interventions: Terameprocol (EM-1421); Drug
Lead sponsor: Erimos Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Colorectal Cancer, Health Status Unknown
Interventions: biologic sample preservation procedure, diagnostic colonoscopy; Other · Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 25 Years to 75 Years
Enrollment: 6,446 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2016
U.S. locations: 4
States / cities: Nashville, Tennessee

Conditions: Lung Neoplasms
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Neuropathic Pain
Interventions: Ziconotide 100 MCG(microgram)/ML Intrathecal Solution, Quantitative sensory testing, Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factor; Drug · Diagnostic Test
Lead sponsor: Albany Medical College; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Albany, New York

Conditions: Colorectal Cancer
Interventions: DNA stability analysis, gene mapping; Genetic
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Up to 69 Years
Enrollment: 598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Duluth, Minnesota

Conditions: Triple Negative Breast Cancer, Natural Killer Cells, BRCA Mutation
Interventions: LiquidBiopsy®, NK VueTM; Device
Lead sponsor: Cynvenio Biosystems; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Westlake Village, California

Conditions: Spinal Tumor
Interventions: Spinal SBRT (Standard Dose), Spinal SBRT (Higher Dose), Gold Seed Implantation, Questionnaires; Radiation · Procedure · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Diabetes Prevention Program; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Glioma, Neurofibromatosis Type 1
Interventions: Not listed
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 2 Years to 21 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 45 Years to 75 Years
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Cancer
Interventions: American Ginseng root; Drug
Lead sponsor: Southern Illinois University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Metastatic Colon Cancer, Stage III Colon Cancer
Interventions: FOLFIRI Protocol, ACTIVE SURVEILLANCE, Nivolumab Protocol, Encorafenib/Binimetinib/Cetuximab Protocol, Trastuzumab + Pertuzumab; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York

Conditions: Colorectal Cancer, Endometrial Cancer, Hereditary Cancer Syndromes
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 1,120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus

Topical Chemoprevention of Skin Cancer Biomarkers

Changes in DNA After Radiation Therapy in Patients With Prostate Cancer

Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer

Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification

Aromatase Inhibitor Clinical Trial

Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers

Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy

A Study to Evaluate the Safety and Efficacy of Intracranial Venous Blood Sampling for Liquid Biopsy in the Diagnosis of Brain Cancers

Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiotherapy

Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer

A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors

Blood and Tissue Sample Collection for Future Colon Cancer Biomarker Studies in Patients Undergoing Colonoscopy

Functional Image and Molecular Markers to Predict Treatment Outcomes in Lung Cancer

Ziconotide as First-Line IDT

Genetic Study in Patients With Stage II or Stage III Colon Cancer

A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.

A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy

Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors

MicroRNAs in Patients With Neurofibromatosis Type 1

PRelationship Between Physical Activity and Cancer Ris

A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction